Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Katja Sockel, Annika Neu, Maren Goeckenjan, Markus Ditschkowski, Inken Hilgendorf, Nicolaus Kröger, Francis A. Ayuk, Friedrich Stoelzel, Jan Moritz Middeke, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Matthias Fante, Daniel Wolff, Thomas Luft, Julia Winkler, Kerstin Schäfer-Eckart, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christian Junghanss, Friederike Wortmann, Susann Winter, Helga Neidlinger, Catrin Theuser, Jan Beyersmann, Martin Bornhaeuser, Sandra Schmeller, Johannes Schetelig

Blood (2024) 144 (14): 1532–1542.

https://doi.org/10.1182/blood.2024024342

Published: 2024

Includes: Supplemental data

Journal Articles

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2023-189047

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

An Open Label Study Comparing Photobiomodulation Therapy to Cryotherapy in Patients at High Risk for Drug-Induced Oral Mucositis

Blood (2023) 142 (Supplement 1): 7081.

https://doi.org/10.1182/blood-2023-180110

Published: 2023

Journal Articles

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, Regina Herbst, Friedrich Stoelzel, Christoph Röllig, Edgar Jost, Richard F. Schlenk, Richard Noppeney, Christian H. Brandts, Utz Krug, Katharina S. Goetze, Sebastian Buske, Axel Florschütz, Jörg Schubert, Bernhard Opitz, Martin Mohren, Eva Eßeling, Stephan von Witzendorff, Marion Subklewe, Martin Kaufmann, Norbert Frickhofen, Christian W Scholz, Kerstin Schäfer-Eckart, Volker Kunzmann, Martin Schmidt-Hieber, Herbert G. Sayer, Andreas Rank, Philipp Hemmati, Frank Schueler, Simone Kowoll, Marina Scheller, Jörg Steighardt, Bayram Edemir, Lutz Peter Mueller, Irit Gliko-Kabir, Beatrice Ludwig-Kraus, Sabine Edemir, Ella Sorani, Mascha Binder, Abi Vainstein, Shaul Kadosh, Cora Gromann, Andreas Wienke, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Martin Bornhaeuser, Christian Junghanss, Carsten Mueller-Tidow

Blood (2022) 140 (Supplement 1): 3338–3340.

https://doi.org/10.1182/blood-2022-166748

Published: 2022

Journal Articles

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Blood (2022) 140 (Supplement 1): 4884–4885.

https://doi.org/10.1182/blood-2022-169326

Published: 2022

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Blood (2022) 140 (Supplement 1): 3327–3328.

https://doi.org/10.1182/blood-2022-159897

Published: 2022

Journal Articles

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Katja Sockel, Sandra Frank, Annika Neu, Markus Ditschkowski, Inken Hilgendorf, Mareen Goeckenjan, Friedrich Stoelzel, Jan Moritz Middeke, Nicolaus Kröger, Francis A. Ayuk, Matthias Eder, Wolfgang Bethge, Jürgen Finke, Hartmut Bertz, Guido Kobbe, Martin Kaufmann, Uwe Platzbecker, David Beverungen, Christoph Schmid, Malte von Bonin, Katharina Egger-Heidrich, Lisa Heberling, Karolin Trautmann-Grill, Raphael Teipel, Gesine Bug, Johanna Tischer, Alessia Fraccaroli, Barbara Holler, Daniel Wolff, Thomas Luft, Wolf Roesler, Kerstin Schäfer-Eckart, Sabine Dressler, Christof Scheid, Udo Holtick, Stefan Klein, Igor Wolfgang Blau, Andreas Burchert, Gerald Wulf, Justin Hasenkamp, Rainer Schwerdtfeger, Stephan Kaun, Christoph Wittke, Friederike Wortmann, Helga Neidlinger, Martin Bornhaeuser, Johannes Schetelig, on Behalf of the German Cooperative Transplant Study Group

Blood (2022) 140 (Supplement 1): 10563–10565.

https://doi.org/10.1182/blood-2022-162673

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Christoph Röllig, Christoph Schliemann, Jan-Henrik Mikesch, Lars Fransecky, Claudia D. Baldus, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Sebastian Scholl, Ulf Schnetzke, Kerstin Schäfer-Eckart, Knut Wendelin, Martin Wermke, Manja Reimann, Frank Fiebig, Theresa Kretschmann, Friedrich Stoelzel, Nael Alakel, Martin Bornhäuser

Blood (2021) 138 (Supplement 1): 2324.

https://doi.org/10.1182/blood-2021-150069

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Blood (2021) 138 (Supplement 1): 173.

https://doi.org/10.1182/blood-2021-145167

Published: 2021

Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 40–42.

https://doi.org/10.1182/blood-2020-137603

Published: 2020

Journal Articles

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-138427

Published: 2020

Journal Articles

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Raynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, MD, Didier Blaise, MD, Emanuele Angelucci, Luca Castagna, Jiri Pavlu, MDMRCP,FRCPath, Gerard Socie, MDPhD, Massimo Martino, Friedrich Stoelzel, PD, MD, Gesine Bug, Yves Chalandon, MD, Benedetto Bruno, MD, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Eolia Brissot, MDPhD, Bipin N. Savani, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-140657

Published: 2020

Journal Articles

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137789

Published: 2020

Journal Articles

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 113.

https://doi.org/10.1182/blood-2019-123047

Published: 2019

Journal Articles

Comparison of a New Reduced Toxicity Myeloablative Treosulfan and Fludarabine Preparative Regimen with Myeloablative Busulfan or Melphalan in Combination with Fludarabine in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes: A Retrospective Matched Pair Analysis of Patients from a Prospective Randomized Trial and the European Blood and Marrow Transplantation Society Registry

Dietrich W. Beelen, Simona Iacobelli, Linda Koster, Dirk-Jan Eikema, Anja van Biezen, Friedrich Stoelzel, MD, Fabio Ciceri, MD, Wolfgang Bethge, Peter Dreger, Eva-Maria Wagner, Péter Reményi, Matthias Stelljes, Miroslaw Markiewicz

Blood (2019) 134 (Supplement_1): 3326.

https://doi.org/10.1182/blood-2019-127108

Published: 2019

Journal Articles

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Sabine Kayser, MD, Michelle A Elliott, MD, Marlise Luskin, MDMS, Andrew M. Brunner, MD, Michael Kramer, M.Sc., Zdenek Racil, MD, Zuzana Sustkova, MD, Petr Cetkovsky, MD MBA, PhD, Jan Novak, MD PhD, Friedrich Stoelzel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD, Uwe Platzbecker, Christoph Röllig, MD MSC, Richard F. Schlenk, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 2693.

https://doi.org/10.1182/blood-2019-125317

Published: 2019

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept

Manja Wobus, PhD, Anna Mies, Valentina Magno, PhD, Cindy Welzel, Susann Winter, PhD, Friedrich Stoelzel, MD, Carsten Werner, PhD, Martin Bornhaeuser, MD, Uwe Platzbecker, MD

Blood (2019) 134 (Supplement_1): 1699.

https://doi.org/10.1182/blood-2019-129814

Published: 2019

NARROW

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

An Open Label Study Comparing Photobiomodulation Therapy to Cryotherapy in Patients at High Risk for Drug-Induced Oral Mucositis

Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Altered Structure and Function of Mesenchymal Stromal Cell-Derived Extracellular Matrix in MDS Can be Restored By Luspatercept

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only